NAMS
NASD NewAmsterdam Pharma Company N.V.$23.81 ↑ +0.00 (+0.00%) Trading Up from the previous close of $23.81
- YTD change
- -32.13%
- vs 20-day SMA
- +2.35%
- vs 200-day SMA
- -24.04%
Price ranges
Price & Performance
-5.52 (-18.82%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 43.6% away from all-time highs of $42.21
- NAMS is down 32% since the beginning of the year
- NAMS is down 16% over the past 12 months
- NAMS is down 6% over the past 1 month
- 21% of all NAMS investors are betting against NAMS
NAMS reads neutral: price sits above one of the two key moving averages, the 12-month move is -16.3%.
- Previous minute
- +$0.00
- Last hour
- +$0.00
- Last 5 days
- +2.10%
- vs 8-day SMA
- +3.65%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
NewAmsterdam Pharma Co. NV is a clinical-stage biopharmaceutical company, which engages in the development of oral, non-statin medicine for patients at high risk of cardiovascular disease with residual elevation of low-density lipoprotein cholesterol. Its lead product candidate, Obicetrapib, is a next-generation, oral, low-dose cholesteryl ester transfer protein inhibitor, which will be used to prevent major adverse cardiovascular events. The company was founded on June 10, 2022 and is headquartered in Naarden, the Netherlands.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
